Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL.
about
Prognostic models for chronic lymphocytic leukaemia: an exemplar systematic review and meta-analysisCombination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemiaAntibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation.Different proliferative and survival capacity of CLL-cells in a newly established in vitro model for pseudofollicles.Outcomes of first line chemotherapy in patients with chronic lymphocytic leukemiaClinical laboratory analysis of immunoglobulin heavy chain variable region genes for chronic lymphocytic leukemia prognosis.Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocationSoluble syndecan-1 (sCD138) as a prognostic factor independent of mutation status in patients with chronic lymphocytic leukemiaFine-mapping of HLA associations with chronic lymphocytic leukemia in US populations.Quantitative protein expression analysis of CLL B cells from mutated and unmutated IgV(H) subgroups using acid-cleavable isotope-coded affinity tag reagents.Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy.Familial chronic lymphocytic leukemia: what does it mean to me?Minimal residual disease detection with tumor-specific CD160 correlates with event-free survival in chronic lymphocytic leukemia.CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potentialEconomic Burden and Quality-of-Life Effects of Chronic Lymphocytic Leukemia: A Systematic Review of the Literature.Combined normal donor and CLL: Single tube ZAP-70 analysis.Immunoglobulin diversity gene usage predicts unfavorable outcome in a subset of chronic lymphocytic leukemia patients.On the TRAIL of a new therapy for leukemia.Monoallelic and biallelic deletions of 13q14 in a group of CLL/SLL patients investigated by CGH Haematological Cancer and SNP array (8x60K).CD38 and chronic lymphocytic leukemia: a decade later.Update on risk-stratified management for chronic lymphocytic leukemia.Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia.Comparative genomic hybridization arrays in clinical pathology: progress and challenges.FISH Analysis for del6q21 and del17p13 in B-cell Chronic Lymphocytic Leukemia in Iranians.The role of prognostic factors in assessing 'high-risk' subgroups of patients with chronic lymphocytic leukemia.Chronic lymphocytic leukemia-associated autoimmune hemolytic anemia.Molecular genetic analysis of haematological malignancies II: Mature lymphoid neoplasms.Hematopoietic stem cell transplantation for chronic lymphocytic leukemia: potential cure for an incurable disease.Validation of a new prognostic index for patients with chronic lymphocytic leukemia.Percentage of smudge cells on routine blood smear predicts survival in chronic lymphocytic leukemiaPhase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia.Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemiaNF-kappaB as a prognostic marker and therapeutic target in chronic lymphocytic leukemia.Biologic agent activity in chronic lymphocytic leukemia: a framework for future therapies.Presenting features and outcome of chronic lymphocytic leukemia patients diagnosed at age 80 years or more. An ICLLSG study.The HemeScan test for genomic prognostic marker assessment in chronic lymphocytic leukemia.Cell surface phenotype profiles distinguish stable and progressive chronic lymphocytic leukemia.Risk Stratification for 4,837 Individuals with Knee Pain Who Receive Physical Therapy Treatment.A Preliminary Risk Stratification Model for Individuals with Neck Pain.The emerging role of estrogen in B cell malignancies.
P2860
Q24186840-E3A7BCE2-C163-4540-BCA8-FAB244ABDC4FQ24681296-A96BE7AD-409C-4752-8143-6E9A5A94DD8AQ33231823-90E9DE21-734D-427C-B171-0759C0745117Q33385676-6D91E837-50FC-4414-9243-C57272054FD3Q33437042-B1EA63AE-1481-4465-BE33-B9C10A8012B5Q33856248-084CAB50-49EA-46AA-96CC-B0B8A41AA83AQ34166551-B44689A6-72F6-41C7-8B2A-709E4497BC17Q34179480-6BDDB318-03A9-4AB3-B5A9-77BB5307C5D9Q34398369-84AB5E14-B669-416F-BCC5-4DFC257B1F7CQ34452722-1A818AA6-DEAC-491F-A884-1EC4DADF3973Q34519192-D764AFD2-0864-4A5F-9BFA-F12D1C9D32B9Q34702451-CE3C0738-1078-446F-AEF5-F28627EC316AQ35040222-3DC60E6D-AE5D-4F76-AFBC-5DD7E9F4CCBBQ35769292-24BB5B44-EDED-4B35-BE41-0EADE208932CQ35887697-670D2895-3D31-42DF-9919-1669E49F7107Q36124374-C587D45F-E903-4FAC-85E5-5494BF64FFDEQ36227244-2367FC9B-4799-4622-A011-62099CABCDC7Q36285964-3532A9CC-2617-4C32-9EDA-95DA82538F2AQ36433299-6168B251-A002-4A4D-8F21-43E5C8C94574Q36615126-AF13621C-982F-4038-8BA1-388635EC5206Q36634599-43054540-A9EE-4BEF-92ED-14DDE587ADBAQ36635059-6B78E166-2938-405C-8951-79147F74874EQ36775601-962488E0-B660-438D-87A2-64C11A450DE7Q36839266-E116F0F6-9B15-4E46-AA41-AC5ED0158D24Q36849336-84E71D59-9E56-475A-8ACA-16B858DA4CA2Q36852852-4ECC8AA8-9C65-4855-81ED-6E842A1475E4Q36872779-27A80B28-98EB-422F-A215-7454D33D025DQ37012037-07A6BBB3-D04E-4C3C-B7FF-AC47C01FD974Q37068125-38EDE7BD-F5BD-43C6-A5B0-B3B1105CC131Q37157694-2C7FA4A6-54EF-46D1-93F0-0D410047C4F6Q37306304-8398A375-74E5-477E-881E-B7FBBF062E93Q37343931-0F50005A-C79D-4998-BF2D-85CB300FA5C3Q37605861-65621A1C-4137-4E5A-A25B-800841EFC92FQ37842484-D4236E4B-DE1E-447C-891F-28182E9A362AQ37879960-95CE0684-1C6C-4C34-9A29-71DFFB2CE255Q38089770-3CA45109-3257-4151-8725-EDC5A0234BD9Q38167332-B1B54D48-5973-4C61-8D93-14BFC8E72E2FQ38845663-DC287D5B-2140-4A2E-A814-9B8B94A59FA3Q39033371-7F5E7CC9-0C90-4D00-AC7A-FF3DEBC174ACQ39456760-69621193-975E-441C-B595-690FFAF3E24A
P2860
Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Prognosis at diagnosis: integr ...... ractice for patients with CLL.
@ast
Prognosis at diagnosis: integr ...... ractice for patients with CLL.
@en
type
label
Prognosis at diagnosis: integr ...... ractice for patients with CLL.
@ast
Prognosis at diagnosis: integr ...... ractice for patients with CLL.
@en
prefLabel
Prognosis at diagnosis: integr ...... ractice for patients with CLL.
@ast
Prognosis at diagnosis: integr ...... ractice for patients with CLL.
@en
P2093
P1433
P1476
Prognosis at diagnosis: integr ...... ractice for patients with CLL.
@en
P2093
Neil E Kay
Susan M Geyer
Tait D Shanafelt
P304
P356
10.1182/BLOOD-2003-07-2281
P407
P577
2003-10-23T00:00:00Z